Hims & Hers Health, Inc. HIMSNYSE

HIMS insider buying and selling from Form 4, 8-K timeline, 13D/13G stakes, dilution and FTD signals from SEC EDGAR, summarized in plain English.

Filings, 30 days6
Latest earnings filingNov 9
Insider buys, 90 days–
Insider sales, 90 days$6M

What the filings say

Hims & Hers Health, Inc. (HIMS) is listed in our Healthcare & pharma group. It filed 6 reports with the SEC in the past 30 days and 32 in the past 90 days. Its most recent earnings-related filing (8-K) was published on Nov 9. Over 90 days, Form 4 filings show no open-market insider buying and insider sales of about $6M. The latest 8-K (Nov 9) covered: Officer or director change. 2 Schedule 13D/13G reports appear in the recent filings.

How to read these filings. An 8-K is the fastest signal: item 2.02 carries earnings, 1.01 a material agreement, 5.02 executive or board changes, 3.02 an unregistered share sale and 5.07 shareholder vote results. A Form 4 shows trades by directors, officers and 10% owners; open-market purchases (code P) are rarer and more closely watched than sales, awards or tax withholding. Schedule 13D and 13G report holders above 5%, with 13D used when the holder may seek influence.

Numbers on this page are compiled automatically from SEC EDGAR. Dollar values of insider trades are the reported shares multiplied by the reported price and exclude derivative positions. Always open the original filing before acting on any figure.

Compiled from public SEC EDGAR data. Times are US Eastern. Titles link to the original filing on sec.gov. Information only — not investment advice. Updated:

Filing timeline

Insider transactions

FiledInsiderTransactionSharesPriceValue
Oct 29, 04:11 PMSoleil Boughton OfficerSale 10b5-13,462$27.6$96K
Oct 15, 04:44 PMSoleil Boughton OfficerSale 10b5-13,461$29.06$101K
Oct 2, 04:32 PMOluyemi Okupe CFOSale 10b5-12,000$29.7$59K
Oct 2, 04:31 PMSoleil Boughton OfficerSale 10b5-13,461$29.17$101K
Sep 23, 12:17 PMOluyemi Okupe CFOSale 10b5-129,277$29.95$877K
Sep 18, 12:17 PMOluyemi Okupe CFOSale 10b5-112,313$28.82$355K
Sep 17, 12:17 PMSoleil Boughton OfficerSale 10b5-16,236$27.86$174K
Sep 17, 12:17 PMMichael Chi COOSale 10b5-114,027$28.39$398K
Sep 17, 12:17 PMMohamed Elshenawy CTOSale 10b5-17,954$28.39$226K
Sep 3, 04:31 PMSoleil Boughton OfficerSale 10b5-13,458$28.33$98K
Aug 27, 09:01 PMAndrew Dudum CEO, Director, 10% ownerOther977,566––
Aug 20, 04:31 PMDeborah M. Autor Officer, DirectorSale 10b5-116,773$27.85$467K
Aug 20, 04:30 PMOluyemi Okupe CFOSale 10b5-14,938$29.99$148K
Aug 20, 04:30 PMSoleil Boughton OfficerSale 10b5-125,111$27.55$692K
Aug 18, 05:04 PMSoleil Boughton OfficerOption/RSU conversion42,261––
Aug 18, 05:04 PMKare Schultz DirectorOption/RSU conversion6,623––
Aug 18, 05:04 PMPatrick Harrison Carroll OfficerOption/RSU conversion26,187––
Aug 18, 05:04 PMAndrew Dudum CEO, Director, 10% ownerOption/RSU conversion154,993––
Aug 18, 05:04 PMMichael Chi COOOption/RSU conversion86,265––
Aug 18, 05:04 PMOluyemi Okupe CFOSale 10b5-164,771$34.05$2.2M
Aug 18, 05:04 PMDeborah M. Autor Officer, DirectorOption/RSU conversion32,920––
Aug 18, 05:03 PMDavid B Wells DirectorOption/RSU conversion778––
Aug 18, 05:03 PMMohamed Elshenawy CTOOption/RSU conversion188,285––
Aug 18, 05:03 PMIrene Becklund OfficerOption/RSU conversion13,685––
Aug 18, 05:03 PMChristopher D Payne DirectorOption/RSU conversion545––

Get the daily US filings summary as a browser notification